Subtype
Bile Duct Neoplasm
CI-CAN-00000563Explore in graph →
Non-malignant224 active trials3 approved drugs29 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000563Explore in graph →
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04087876 | Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations | no longer available | — | — | Basilea PharmaceuticaINDUSTRY | 0 | Apr 6, 2025 | clinicaltrials |
| NCT03414489 | Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) | no longer available | — | — | RedHill Biopharma LimitedINDUSTRY | 0 | Mar 18, 2025 |
| clinicaltrials |
Data updated 22 days agoSource updated Apr 6, 2025source: clinicaltrials